Comparison of a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV plus AURORA 1 studies and ALMS (LUPUS 2024) - Feb 25, 2024 - Abstract #P87; Pres time: Mar 21, 2024; 12:45 PM - 01:30 PM; "In ALMS, MMF (3 g/day) or intravenous cyclophosphamide (IVC; 0. Triple therapy is also superior in achieving early proteinuria milestones. These data provide further support for use of combination therapy as initial treatment in patients with active LN and to minimizing patient exposure to GCs, as proposed by the 2023 EULAR guidelines"
Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis
|
|
Maria Dall’Era1,2; Kenneth Kalunian3; Anca Askanase4; Neil Solomons5; Matt Truman2; Lucy Hodge2; Ernie Yap2
|